These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

518 related articles for article (PubMed ID: 28239472)

  • 1. Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody.
    Donahue RN; Lepone LM; Grenga I; Jochems C; Fantini M; Madan RA; Heery CR; Gulley JL; Schlom J
    J Immunother Cancer; 2017; 5():20. PubMed ID: 28239472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells.
    Boyerinas B; Jochems C; Fantini M; Heery CR; Gulley JL; Tsang KY; Schlom J
    Cancer Immunol Res; 2015 Oct; 3(10):1148-1157. PubMed ID: 26014098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Avelumab: combining immune checkpoint inhibition and antibody-dependent cytotoxicity.
    Hamilton G; Rath B
    Expert Opin Biol Ther; 2017 Apr; 17(4):515-523. PubMed ID: 28274143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab.
    Fujii R; Friedman ER; Richards J; Tsang KY; Heery CR; Schlom J; Hodge JW
    Oncotarget; 2016 Jun; 7(23):33498-511. PubMed ID: 27172898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells.
    Juliá EP; Amante A; Pampena MB; Mordoh J; Levy EM
    Front Immunol; 2018; 9():2140. PubMed ID: 30294328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ADCC employing an NK cell line (haNK) expressing the high affinity CD16 allele with avelumab, an anti-PD-L1 antibody.
    Jochems C; Hodge JW; Fantini M; Tsang KY; Vandeveer AJ; Gulley JL; Schlom J
    Int J Cancer; 2017 Aug; 141(3):583-593. PubMed ID: 28477372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Malignant Mesothelioma Effusions Are Infiltrated by CD3
    Khanna S; Thomas A; Abate-Daga D; Zhang J; Morrow B; Steinberg SM; Orlandi A; Ferroni P; Schlom J; Guadagni F; Hassan R
    J Thorac Oncol; 2016 Nov; 11(11):1993-2005. PubMed ID: 27544053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-PD-L1/TGFβR2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis.
    Grenga I; Donahue RN; Gargulak ML; Lepone LM; Roselli M; Bilusic M; Schlom J
    Urol Oncol; 2018 Mar; 36(3):93.e1-93.e11. PubMed ID: 29103968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Near infrared photoimmunotherapy with avelumab, an anti-programmed death-ligand 1 (PD-L1) antibody.
    Nagaya T; Nakamura Y; Sato K; Harada T; Choyke PL; Hodge JW; Schlom J; Kobayashi H
    Oncotarget; 2017 Jan; 8(5):8807-8817. PubMed ID: 27716622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma.
    Rajan A; Heery CR; Thomas A; Mammen AL; Perry S; O'Sullivan Coyne G; Guha U; Berman A; Szabo E; Madan RA; Ballester LY; Pittaluga S; Donahue RN; Tsai YT; Lepone LM; Chin K; Ginty F; Sood A; Hewitt SM; Schlom J; Hassan R; Gulley JL
    J Immunother Cancer; 2019 Oct; 7(1):269. PubMed ID: 31639039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-L1 inhibition with avelumab for metastatic Merkel cell carcinoma.
    Gaiser MR; Bongiorno M; Brownell I
    Expert Rev Clin Pharmacol; 2018 Apr; 11(4):345-359. PubMed ID: 29478343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Which place for avelumab in the management of urothelial carcinoma?
    Larroquette M; Gross-Goupil M; Daste A; Robert G; Ravaud A; Domblides C
    Expert Opin Biol Ther; 2019 Sep; 19(9):863-870. PubMed ID: 31286802
    [No Abstract]   [Full Text] [Related]  

  • 13. Blocking PD-1/PD-L1 by an ADCC enhanced anti-B7-H3/PD-1 fusion protein engages immune activation and cytotoxicity.
    Xu Y; Xiao Y; Luo C; Liu Q; Wei A; Yang Y; Zhao L; Wang Y
    Int Immunopharmacol; 2020 Jul; 84():106584. PubMed ID: 32422527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial.
    Chung HC; Arkenau HT; Lee J; Rha SY; Oh DY; Wyrwicz L; Kang YK; Lee KW; Infante JR; Lee SS; Kemeny M; Keilholz U; Melichar B; Mita A; Plummer R; Smith D; Gelb AB; Xiong H; Hong J; Chand V; Safran H
    J Immunother Cancer; 2019 Feb; 7(1):30. PubMed ID: 30717797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines.
    Park JE; Kim SE; Keam B; Park HR; Kim S; Kim M; Kim TM; Doh J; Kim DW; Heo DS
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32830112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial.
    Hassan R; Thomas A; Nemunaitis JJ; Patel MR; Bennouna J; Chen FL; Delord JP; Dowlati A; Kochuparambil ST; Taylor MH; Powderly JD; Vaishampayan UN; Verschraegen C; Grote HJ; von Heydebreck A; Chin K; Gulley JL
    JAMA Oncol; 2019 Mar; 5(3):351-357. PubMed ID: 30605211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immuno-PET Imaging of the Programmed Cell Death-1 Ligand (PD-L1) Using a Zirconium-89 Labeled Therapeutic Antibody, Avelumab.
    Jagoda EM; Vasalatiy O; Basuli F; Opina ACL; Williams MR; Wong K; Lane KC; Adler S; Ton AT; Szajek LP; Xu B; Butcher D; Edmondson EF; Swenson RE; Greiner J; Gulley J; Eary J; Choyke PL
    Mol Imaging; 2019; 18():1536012119829986. PubMed ID: 31044647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials.
    Kelly K; Infante JR; Taylor MH; Patel MR; Wong DJ; Iannotti N; Mehnert JM; Loos AH; Koch H; Speit I; Gulley JL
    Cancer; 2018 May; 124(9):2010-2017. PubMed ID: 29469949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic Immunotherapy of Non-Muscle Invasive Mouse Bladder Cancer with Avelumab, an Anti-PD-L1 Immune Checkpoint Inhibitor.
    Vandeveer AJ; Fallon JK; Tighe R; Sabzevari H; Schlom J; Greiner JW
    Cancer Immunol Res; 2016 May; 4(5):452-62. PubMed ID: 26921031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.